TABLE 1.
Proliferation of splenocytes obtained from B. mallei-vaccinated BALB/c mice
| Group vaccinateda | [3H]thymidine incorporated (cpm)b in:
|
|||
|---|---|---|---|---|
| Medium | Medium with stimulating antigen
|
|||
| Cellc | ConA | LPS | ||
| HKGB15 | 742 ± 159 | 16,922 ± 1,213* | 139,369 ± 13,197 | 52,163 ± 1,155 |
| IRGB15 | 542 ± 459 | 16,215 ± 3,163* | 137,576 ± 6,070 | 46,263 ± 3,338 |
| CapGB15 | 752 ± 164 | 15,962 ± 4,474* | 141,252 ± 23,944 | 42,178 ± 2,759 |
| Adjuvant | 554 ± 129 | 10,214 ± 1,297 (HK) | 114,759 ± 12,263 | 42,428 ± 376 |
| Adjuvant | 554 ± 129 | 12,071 ± 1,096 (IR) | 114,759 ± 12,263 | 42,428 ± 376 |
| Adjuvant | 554 ± 129 | 9,362 ± 1,120 (Cap) | 114,759 ± 12,263 | 42,428 ± 376 |
a
There were four mice per group, and spleens were processed as described in Materials and Methods.
b
Results are means ± SDs. *, P < 0.01 for comparison with the homologous adjuvant control.
c
“Cell” refers to the homologous stimulating antigen, except for mice treated with adjuvant only. Abbreviations in parentheses represent stimulating antigens: HK, heat-killed GB15; IR, irradiation-inactivated GB15; Cap, capsule-negative GB15.